Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis
Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis
复制标题
DOI：
10.1001/archopht.116.11.1456
复制
发表时间：
1998-11-01
影响因子：
--
通讯作者：
Dick, AD
中科院分区：
文献类型：
--
作者：
Dees, C;Arnold, JJ;Dick, AD
目的：探讨内源性后葡萄膜炎的一种公认的视力威胁并发症——脉络膜新生血管（CNV）能否通过免疫抑制来解决和维持视力。患者和方法：14例（17只眼）CNV合并内源性后葡萄膜炎纳入一项开放研究。年龄从5岁到51岁不等。3眼为中央凹外CNV， 6眼为中央凹旁CNV， 8眼为中央凹下CNV。3名患者接受单疗程的口服皮质类固醇治疗，2名患者额外服用环孢素长达2年，9名患者继续接受低剂量免疫抑制药物联合治疗。结果：中位随访15个月（7个月至6年半），17只眼中有9只眼视力改善；6例视力维持在1条斯奈伦线以内，2例失去2条斯奈伦线。血管造影显示，13只眼CNV消退，3只眼消退后复发，4只眼好转但持续。结论：这些结果支持免疫抑制治疗内源性后葡萄膜炎相关CNV的作用。
Objective: To determine whether resolution of choroidal neovascularization (CNV), a recognized sight-threatening complication of endogenous posterior uveitis, and maintenance of vision could be achieved with immunosuppression.Patients and Methods: Fourteen patients (17 eyes) with CNV associated with endogenous posterior uveitis were enrolled in an open study. Ages ranged from 5 to 51 years. Three eyes had extrafoveal CNV, 6 juxtafoveal, and 8 subfoveal. Three patients were treated with a single course of oral corticosteroids, 2 had additional cyclosporine for up to 2 years, and 9 continued to receive a low-dose regimen of a combination of immunosuppressive drugs.Results: After a median follow-up of 15 months (range, 7 months to 6 1/2 years), 9 of 17 eyes had an improvement in visual acuity; 6 remained within 1 Snellen line of initial visual acuity, and 2 had lost 2 Snellen lines. Angiographically, CNV resolved in 13 eyes, resolved then recurred in 3, and improved but persisted in 4.Conclusion: These results support a role for immunosuppressive therapy in the treatment of CNV associated with endogenous posterior uveitis.